Relapsed small-cell lung cancer: platinum re-challenge or not

Rossi, Antonio

doi:10.21037/jtd.2016.09.28

Cited by 9 publications

(5 citation statements)

References 19 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small-Cell Lung Cancer (SCLC) is sensitive to first line platinum-doublet chemotherapy (PDCT), with objective response in more than 50% of the patients [ 1 ]. Sensitivity to PDCT is usually transient and followed by a PDCT refractory disease resulting in a median progression-free survival (PFS) of around five months [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy

et al. 2020

View full text Add to dashboard Cite

Objectives The aim was to analyse the tumor expression of Notch1, Hes1, Ascl1, and DLL3 in Small-Cell Lung Cancer (SCLC) and each such biomarker’s potential association with clinical characteristics and prognosis after platinum-doublet chemotherapy (PDCT). Material and methods The protein expression of the biomarkers was evaluated using immunohistochemistry. Patients were categorized according to their sensitivity to first line PDCT: with a Progression-free survival (PFS) ≥ 3 months after completion of treatment considered “sensitive” and < 3 months after completion of treatment considered “refractory”. PFS and overall survival were computed using Kaplan-Meier curves with 95% confidence interval. Results and conclusion The study included 46 patients, with 21 and 25 of the patients having “sensitive” and “refractory” disease, respectively. The majority of patients had a high DLL3 expression (n = 38), while a minority had Notch 1-high expression (n = 10). The chi-square test showed that there was a statistically significant negative association between Notch1 and Ascl1 expression (p = 0.013). The overall survival for patients with Notch1- high vs. low expression was 8.1 vs. 12.4 months, respectively (p = 0.036). Notch1 expression was an independent prognostic factor in the multivariate analysis (p = 0.02). No other biomarker showed any prognostic impact in this highly selected SCLC cohort. DLL3 is highly expressed in the majority of advanced staged SCLC cases, as expected. In the same patient population, Notch1 expression might have a potential prognostic implication, by driving a non-neuroendocrine differentiation process. Given the small number of cases with Notch1 high expression, the results of this study needs to be confirmed on a larger cohort.

show abstract

Section: Introductionmentioning

confidence: 99%

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[2][3][4] Chemotherapy has been the standard of systemic treatment for SCLC for several decades; however, although SCLC is initially responsive to chemotherapy, relapse is common and the response to second-line therapy is poor, with survival of less than 6 months. 5,6 In addition, the overall median survival of patients with SCLC was found to be unchanged between 1983 and 2012, remaining at just 7 months throughout the period and thus highlighting the urgent need for novel treatments. 3,4 More recent studies of combination therapies, such as the addition of atezolizumab to carboplatin and etoposide chemotherapies, have demonstrated significantly longer overall survival and progression-free survival rates compared with placebo; however, the gains are modest (median 2 months' additional overall survival compared with placebo).…”

Section: Introductionmentioning

confidence: 99%

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

Bauer

Besse

Martinez-Martí

et al. 2019

Journal of Thoracic Oncology

View full text Add to dashboard Cite

“…There is a desperate need for new approaches in this setting. An additional benefit of lurbinectedin as second-line therapy in patients with sensitive SCLC is prolongation of the platinum-free interval, which may further re-sensitize tumors to the original therapy for a third-line therapy [24]. After lurbinectedin, 7 of 20 patients (35 %) received further platinum.…”

Section: Discussionmentioning

confidence: 99%

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

et al. 2020

View full text Add to dashboard Cite

The National Comprehensive Cancer Network guidelines recommend re-challenge with the first-line treatment for relapsed small cell lung cancer (SCLC) with chemotherapy-free interval (CTFI)≥180 days. A phase II study (NCT02454972) showed remarkable antitumor activity in SCLC patients treated with lurbinectedin 3.2 mg/m 2 1-h intravenous infusion every 3 weeks as second-line therapy. We report results for the pre-planned subset of patients with CTFI ≥ 180 days.

show abstract

Relapsed small-cell lung cancer: platinum re-challenge or not

Cited by 9 publications

References 19 publications

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy

The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

Contact Info

Product

Resources

About